Neumora Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Trading Arrangements
The following table describes, for the three months ended September 30, 2024, each trading arrangement for the purchase or sale of Company securities adopted, modified or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
| Trading Arrangement | |||||
|---|---|---|---|---|---|
| Name(Title) · Action · Date · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares to be Sold · Expiration Date | |||||
| Daljit (Bill) Singh Aurora(Chief Strategy Officer) | Amend(1) | September 10, 2024 | X | 57,350 | December 10, 2025 |
| Michael Milligan(SVP and Principal Accounting Officer) | Adopt | August 30, 2024 | X | 20,000 | November 28, 2025 |
*Intended to satisfy the affirmative defense of Rule 10b5-1(c)
**Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
(1) Changed the timing and price limits of sales under the trading arrangement originally adopted on April 22, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.